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Abstract  
Canine degenerative myelopathy (DM) is a progressive neurological disorder that maybe considered 
to be a large animal model for specific forms of the fatal human disease, familial Amytrophic Lateral 
Sclerosis (fALS).  DM is associated with a c118G>A mutation of the superoxide dismutase 1 (Sod1) 
gene and a significant proportion of cases are inherited in an autosomal recessive manner in 
contrast to the largely, but not exclusively, dominant mode of inheritance in fALS.  The consensus 
view is that these Sod1/SOD1 mutations results in a toxic gain of function but the mechanisms 
remain unclear.  Here we used an in vitro neuroblastoma cell line transfection system to monitor 
wild type and mutant forms of SOD1 fusion proteins containing either a Cherry or an enhanced 
green fluorescent protein (EGFP) tag.  These fusion proteins retained SOD1 enzymatic activity on a 
native gel assay system.  We demonstrate that SOD1 aggregate density is significantly higher in DM 
transfectants compared to wild type and show by co-immunoprecipitation and confocal microscopy, 
evidence for a potential interaction between wild type and mutant forms of SOD1 in co-transfected 
cells.  While in vitro studies have shown SOD1 heterodimer formation in fALS models, this is the first 
report for DM SOD1.  Therefore, despite for the majority of cases there is a difference in the mode 
of inheritance between fALS and DM, a similar interaction between wild type and mutant SOD1 
forms can occur.  Clarifying the role of SOD1 in DM may also be of benefit to understanding the role 
of SOD1 in fALS. 
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Introduction 
Canine degenerative myelopathy (DM) is a progressive neurological disorder of the CNS that 
develops in aged dogs causing paresis of pelvic limbs that can progress to tetraplegia and ultimately 
death.  The neurological signs are consistent with an upper motor neuron disease although there are 
lower motor neuron signs when euthanasia has been delayed (Griffiths and Duncan, 1975; Shelton 
et al., 2012).  Although initially reported to affect mainly German Shepherd dogs (Averill, Jr., 1973; 
Griffiths and Duncan, 1975; Johnston et al., 2000), a range of small and large breeds have now been 
confirmed that develop the disease (Awano et al., 2009; Wininger et al., 2011; Zeng et al., 2014).  
The disease progression is rapid and ultimately results in euthanasia which is often elected when 
dogs reach a paraplegic state (Coates and Wininger, 2010; Griffiths and Duncan, 1975).  The 
pathology of DM is characterised by an axonopathy and secondary myelin loss in the lateral columns 
of the ventral faniculi of the spinal cord, primarily within the thoracic/lumber intumescences 
(Johnston et al., 2000).  Gliosis is widespread in the spinal cord (Johnston et al., 2000), and there are 
reports of neuronal and synaptic loss affecting both somatic sensory and motor tracts (Ogawa et al., 
2014). 
Diagnosis of DM in the clinic is achieved by exclusion of a wide range of common spinal cord 
diseases although a strong association has been found in cases that harbour a point mutation of the 
Sod1 gene (c118G>A) resulting in a predicted E40K amino acid substitution (Awano et al., 2009; 
Shafie et al., 2014; Zeng et al., 2014).  The inheritance appears to be primarily autosomal recessive 
with Awano reporting on 100 cases across five breeds that 96% homozygotes (A/A) in DM diagnosed 
dogs although 34% (n=437) of the control group were also homozygotes (Awano et al., 2009).  A 
similar pattern was reported in a more expansive study that confirmed eight DM cases were 
heterozygotes (A/G) (Zeng et al., 2014).  An unbiased analysis by assessing dogs at a presymptomatic 
age (<6 years) then at a later age (>10 years) found that the incidence of these cases presenting 
clinical signs were 60% A/A, 4% G/A and 6% G/G suggesting characteristics of variable penetrance 
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(Zeng et al., 2014).  Interestingly, another Sod1 gene mutation (c52A>T) has been reported which, to 
date, is only associated with the Bernese Mountain dog breed (Wininger et al., 2011).  In addition, 
only a limited number of Bernese Mountain dogs were genotyped as heterozygotes for both c52A>T 
and c118G>A mutations and confirmed as DM cases by histopathology examination.  This raises the 
possibility that compound heterozygotes may be a risk of developing DM (Pfahler et al., 2014; 
Wininger et al., 2011; Zeng et al., 2014).  A potential modifier gene Sp110 has been reported that 
may influence the incidence of penetrance and possibly the age of onset (Ivansson et al., 2016). 
The association between mutation(s) of the Sod1 gene together with the clinical features of DM has 
led to a proposal that DM may represent a natural and valid large animal model for specific forms of 
fALS.  In fALS, an association with a mutation in the SOD1 gene occurs in approximately 20% of cases 
(Bunton-Stasyshyn et al., 2015) and up to 190 mutations have now been identified with an a 
seemingly unbiased distribution across the protein.  To date there are no reports of a human SOD1 
mutation that is equivalent to the DM c118G>A.  However, disease penetrance rates in fALS 
associated with a SOD1 gene mutation is also complex; most are primarily inherited in a dominant 
mode although there are cases of recessive inheritance in fALS due to compound heterozygosity 
(Hand et al., 2001; Pasinelli and Brown, 2006) and also homozygote pedigrees of the D90A SOD1 
mutation (Andersen et al., 1995). 
As with the spectrum of SOD1 mutations in fALS, the causative relationship between the Sod1 
mutation and the development of DM is currently unknown.  It is generally agreed that in fALS and 
DM there is a toxic gain of function rather than a loss of function (Reaume et al., 1996) although a 
specific mechanism or indeed mechanisms common to the range of SOD1 mutants has not been 
identified.  A number of transfection based studies have established that DM SOD1 can form 
aggregates in the cytoplasm of cultured cells including the embryonic kidney HEK293A and the 
neuroblastoma NSC34 cell lines with subsequent altered detergent solubility properties (Crisp et al., 
2013; Nakamae et al., 2015).  Similar alterations in conformation and a propensity to form 
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aggregates have also been observed in a number of fALS SOD1 mutations (Orrell, 2000; Pickles and 
Vande, 2012; Prudencio et al., 2009b; Rakhit and Chakrabartty, 2006).  A recent study has described 
SOD1 aggregate accumulation in neurons and astrocytes of affected dogs suggesting a non-cell-
autonomous process in DM (Kobatake et al., 2017).  There are common degradation mechanisms for 
mutant SOD1 in DM and fALS, for example perturbation of the proteasome pathway (Nakamae et 
al., 2015).  However, an intriguing and fundamental difference between DM and fALS is the high 
frequency of recessive cases in DM compared to high incidence of dominant inheritance in fALS 
(Nardone et al., 2016).  WT and mutant SOD1 complexes can arise in fALS that appear to have a 
reduced propensity to form aggregates (Prudencio et al., 2009a; Weydert and Cullen, 2010; Witan et 
al., 2008; Witan et al., 2009) although soluble forms of SOD1, including heterodimers and trimeric 
complexes, may actually be more toxic than large SOD1 aggregates (Brotherton et al., 2013; 
Weichert et al., 2014; Zhu et al., 2018; Proctor et al., 2016).  In asymptomatic and symptomatic 
heterozygous dogs, SOD1 aggregates have been observed (Awano et al., 2009; Nakamae et al., 
2015).  It is unclear if these aggregates contain homodimeric or heterodimeric complexes and if they 
have a functional relevance to disease development. 
Here, the expression of a panel of WT and DM Sod1 cDNA constructs was used to track the 
distribution of fluorescent fusion SOD1 proteins in transiently transfected neuroblastoma cells.  This 
confirmed that an increase in aggregate accumulation occurs in DM-SOD1 transfected cells 
compared to WT SOD1 transfectants.  Furthermore, we present a combination of co-
immunoprecipitation (IP) and confocal microscopy evidence that is consistent with a protein:protein 
interaction between the WT and mutant forms of SOD1 in cellular aggregates.  These novel findings 
suggest the c118G>A Sod1 mutation alters some of the biochemical properties of SOD1 probably 
associated with the accumulation of aggregates.   
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Materials and Methods 
Construction of Sod1 recombinants 
Total cellular RNA was prepared from WT and DM T12 spinal cords using RNABee (Amsbio, UK) 
according to manufacturer’s protocol.  Random hexamer (Life Technologies, UK) primed cDNA 
synthesis was performed on 2 µg of RNA using SuperScript III following supplier’s guidelines.  Both 
WT and DM Sod1 cDNAs were subcloned into each of the amino fluorescent reporter vectors pEGFP-
C3 and pCherry-C1 to generate (pWT-EGFP and pDM-EGFP) and (pWT-Cherry and pDM-Cherry).  Two 
pairs of restriction enzyme site (in bold typeface) anchored PCR primers : (Fw XhoI 5/-CTC GAG ATG 
GAG ATG AAG GCC GTG TGC GTG-3//(Rv -HindIII 5/-AAG CTT TTA TTG GGC GAT CCC AAT GAC ACC –
3/.) and (Fw -XhoI 5/-CTC GAG ATG GAG ATG AAG GCC GTG TGC GTG-3/)/(Rv: BamHI 5/-GGA TCC TTA 
TTG GGC GAT CCC AAT GAC ACC-3/) were used to amplify the 462 bp WT and DM Sod1 cDNAs 
corresponding to the 154 amino acid open reading frame (ORF).  Using standard molecular 
techniques, amplicons were synthesised using the high fidelity proofreading EasyA Polymerase 
(Stratagene, USA) and cloned into the T/A vector pSC-A (Stratagene, USA).  The inserts were released 
from the pSC-A recombinants by appropriate restriction enzyme digestion and covalently linked in-
frame into at the corresponding sites in the multiple cloning site of the fluorescent tagged 
expression vectors pEGFP-C3 and pCherry-C1. 
Cell culture 
The SK-N-SH human neuroblastoma cell line (Helson et al., 1975) was used in this study.  The cell line 
was maintained at 37 0C, 5 % CO2 in DMEM high glucose medium (Invitrogen, UK), 10 % fetal bovine 
serum (FBS, Gibco, UK) and 1 % Penicillin-Streptomycin for a maximum of 20 passages.  
Transfection, cell lysis and fluorescence microscopy 
Cells were seeded on 13 mm Poly-L-Lysine treated coverslips in four-well plates at a cell density of 
5x104 per well or on six-well plates at 4x105 per well and incubated overnight.  Transfections were 
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performed using Lipofectamine® LTX with Plus™ Reagent (Invitrogen, UK) following manufacturer’s 
recommendations and either fixed with 4 % paraformaldehyde (PFA) or harvested at the appropriate 
time point.  The cells were visualised on a fluorescence microscope (IX70, Olympus, UK) and images 
captured using Image Pro Plus software (Media Cybernetics, USA).  Nuclei were visualised in cells by 
treatment with 4',6-diamidino-2-phenylindole (DAPI, Sigma, UK).  Cell counting was performed using 
Image J software.  For each plasmid, three fields from four independent experiments were captured 
and the number of transfected cells with aggregates were quantified.  For confocal microscopy, 
fluorescent samples were imaged using a 1.4NA Plan-Apochromat oil immersion objective lens fitted 
to a Zeiss LSM710 meta confocal microscope.  The 405 nm laser line was utilised for DAPI, the 488 
nm laser for green fluorescent protein (GFP) and the 561 nm laser for mCherry.  Weighted co-
localization coefficients were generated using Zen 2012 software (Zeiss, DE).  All images have voxel 
sizes of 0.08 microns in each of x, y and z the number of confocal planes is one.  
Cell lysates were prepared as described previously (McLaughlin et al., 2006), with a cell lysate buffer 
containing 1× TBS, 1 % Triton X-100, 1 mM EDTA, 1 mM Na Vanadate, 1 mM Na Pyrophosphate, and 
1× Protease Inhibitor Cocktail (Invitrogen, UK).  Cell lysates were mixed thoroughly by rotating at 4 
°C for 30 minutes.  Following centrifugation at 5,000 × g at 4 °C for 10 minutes, the supernatant and 
pellet fractions were collected and stored.  The supernatant was assayed for protein content using 
the BCA assay system (Thermo scientific, UK) with bovine serum albumin as a reference standard. 
SOD1 activity analysis using a native gel nitroblue tetrazolium (NBT) reduction assay system 
SOD1 enzymatic activity was measured using a native gel NBT reduction system (Rakhit and 
Chakrabartty, 2006; Weydert and Cullen, 2010).  This assay is based on the ability of SOD1 to retain 
its free radical savaging activity under native gel electrophoresis conditions thus inhibiting the 
reduction of tetrazolium to a blue complex generating white band(s) at the location of an active 
enzyme complex.  Samples were mixed with a solution of glycerol and bromophenol blue and loaded 
onto a 10 % acrylamide native resolving gel with a 4 % stacking gel without SDS or dithiothreitol.  
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Gels were electrophoresed at 20 mA with chilled running buffer (25 mM Tris, 200 mM Glycine pH 
8.3), stained with 1.23 mM NBT for 15 minutes then incubated with 28 mM TEMED and 280 mM 
riboflavin for 15 minutes in the dark.  Following rinsing with MilliQ water, the gels were exposed to 
daylight and the colour reaction was allowed to develop over 5 to10 minutes. 
Western blotting 
Western blotting procedure was performed as described previously (McLaughlin et al., 2002).  SDS 
PAGE was performed using NuPAGE®Novex® 4 – 12 % Bis-Tris Protein Gels, (Life Technologies, UK), 
the gel was transferred to nitrocellulose sheets using the iBlot® Transfer System, (Life Technologies, 
UK), blocked with 5 % non-fat milk powder in 1× Tris-buffered saline with Tween 20 (TTBS) and 
probed with the following primary antibodies anti-Cu/Zn SOD1 at 1/2000 dilution (AD1 SOD1-100, 
rabbit polyclonal from ENZO Life Science, USA), anti-GFP at 1/5000 (Abcam, UK, goat polyclonal Ab 
6673), anti-Cherry at1/2000 (Abcam, UK, mouse monoclonal 125096) anti-β-Actin at 1/100,000 
(Sigma Aldrich, UK mouse monoclonal clone AC-15, A-5441).  Following several washes, 
nitrocellulose membranes were incubated with horseradish peroxidase-linked (HRP) secondary 
antibody in 5 % milk powder in TTBS and the immunocomplex detected by chemiluninescence ECL 
reaction (Thermo Fisher Scientific, UK).  The signal intensity of the protein bands were quantified 
using Image J software (National Institute of Health, USA).  
Immunoprecipitation 
Rabbit polyclonal antibodies against GFP (Abcam ab290, 25 µg), Cherry (Abcam ab183628, 20 µg) 
and 10 µl of normal rabbit sera were coupled to 200 µl of settled beads of rmp Protein A Sepharose 
Fast Flow (GE healthcare, UK) as previously described (McLaughlin et al., 2002).  In brief, Protein A 
beads were incubated with the appropriate antibody for two hours at 4 oC with rotation, washed 
three times with 100 mM sodium borate pH 9.2 and incubated with 200 mM dimethyl pimelimidate 
for one hour.  Beads were then washed with 50 mM glycine pH 2.5 to remove unbound 
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immunoglobulins and resuspended in 1 ml of 50 mM Tris pH 8.0.  The immunoprecipitation reactions 
were performed by incubating 30 µg of cell lysate with 50 µl of antibody coupled beads in 500 µl 
volume of lysis buffer (10 mM Hepes, 120 mM NaCl2, 1 % triton-X-100 containing protease and 
phosphatase inhibitors) with rotation over night at 4 0C.  The beads were pelleted by centrifugation, 
washed with lysis buffer and re-suspended in 1 ml of 10 mM tris pH 8.0.  Each sample was split into 
two aliquots, centrifuged and the immunocomplex denatured for SDS-PAGE analysis.  Each aliquot 
was processed by Western blotting using a goat anti GFP at 1/3,000 (Abcam ab6673) and mouse 
monoclonal anti-Cherry antibody at 1/1,000 dilutions (Abcam ab125096).  Each gel also had 1.5 µg of 
the appropriate cell lysate as a positive control. 
Statistical analysis 
All statistical analyses and graphs in this study were analysed by using GraphPad Prism 5.0 
(GraphPad Software, USA).  Where data sets had equal variance, statistical analysis was performed 
using a two tailed Student’s t-test with confidence intervals of 95 % and the Welch t-test was 
employed where the variance between two data sets were unequal. Data are reported as 
mean±SEM, P value and F ratio. 
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Results 
Characterisation of fluorescently tagged SOD1 fusion proteins  
Transfected neuroblastoma cell line SK-N-SH lysates analysed by western blotting confirmed the 
recombinants were expressed in-frame (Figure 1A).  The anti-SOD1 antibody detected the 
endogenous SOD1 at ~20 kDa and the fusion proteins at the predicted molecular weight of ~48 kDa.  
This was determined with either anti-EGFP or anti-Cherry antibodies that detected the unconjugated 
EGFP or Cherry moieties at ~27 kDa and the fusion protein at ~48 kDa.  The relative expression level 
was comparable between plasmids as indicted by the similar levels of β-actin. 
Mean transfection rates from three independent experiments were 40.3±8%, 39.9±13.9%, 
27.7±4.6% and 41.4±8% (mean±SEM) with SK-N-SH cells transfected with pWT-EGFP, pDM-EGFP, 
pWT-Cherry and pDM-Cherry respectively for 48 hours.  As depicted in Figure 1B, similar to the 
empty vectors, the majority of SK-N-SH transfected cells expressing pWT-EGFP and pWT-Cherry 
displayed a uniform pattern of green and red fluorescence respectively in the cytoplasm.  In 
contrast, a bright punctate cytoplasmic pattern (identified by arrows), possibly indicative of protein 
aggregates, was evident in a higher percentage of cells expressing DM cDNAs compared to WT 
constructs (16.7±2.0% of pDM-EGFP compared to 5.8±2.0% pWT-EGFP and 15.8±5.1 pDM-Cherry 
compared to 2.6±0.6% pWT-Cherry transfectants (mean±SEM) (Figure 1C).  The difference in the 
density of aggregate containing cells was statistically significant (p=0.0086 for pWT-EGFP versus 
pDM-EGFP (Students t-test, F ratio of 1.02) and p= 0.0145 for pWT-Cherry versus pDM-Cherry 
(Welch t-test, since F ratio =18.5, P=0.03 confirming unequal variance between data sets). 
SOD1 enzymatic activity of the fusion proteins was analysed using the native gel NBT system (Figure 
2A) where SOD1 scavenging activity can be visualised on the gel.  Two prominent bands of activity 
were observed in non-transfected cells that may represent both copper/zinc SOD and manganese 
SOD (indicated with black arrowheads).  Several additional activity bands were observed with pWT-
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EGFP (Lane 2) and pDM-EGFP (Lane 3) (indicated by the green arrows) and in pWT-Cherry (Lane 5) 
and pDM-Cherry transfectants (Lane 6) (indicated with the red arrows).  The signal intensity with 
pDM-Cherry was routinely lower compared to the other Sod1 fusion constructs and tended to fade 
during the reaction process.  Analysis of lysates prepared from co-transfected cells (pWT-EGFP/pDM-
Cherry) (Lane 4) and (pDM-EGFP/pWT-Cherry) (Lane 7), also showed additional bands compared to 
the non-transfected cells (Lane 1).  The banding profile observed with the NBT system is consistent 
with the fusion proteins retaining SOD1 enzymatic activity and is in agreement with reports on the 
activities of human SOD1 constructs using this method (Weichert et al., 2014; Weydert and Cullen, 
2010; Witan et al., 2009).  The variability between the WT and DM SOD1 banding patterns may 
indicate changes in the composition of proteins associated with SOD1 under native gel conditions.  
Western blotting analysis (Figure 2B) confirmed the presence of the different SOD1-fusion proteins 
in these lysates.   
Co-expression of WT and mutant Sod1 cDNAs in transfected cells 
SK-N-SH cells were co-transfected (Figure 3) with combinations of pWT-EGFP/pDM-Cherry (Panels 1 
and 2) and pWT-Cherry/pDM-EGFP for 48 hrs (Panels 3 and 4) and analysed for protein co-
localisation by confocal microscopy.  Aggregates corresponding to bright fluorescent punctuate 
spots were detected in the green channel (WT-EGFP Panel 1, and DM-EGFP Panel 3) and also in the 
red channel (DM-Cherry Panel 1, and WT-Cherry Panel 3).  These intense areas of fluorescence were 
unevenly distributed in the cytoplasm surrounding the nucleus.  The merged images displayed areas 
of punctate yellow fluorescence (Panels 1 and 3) suggests a co-localisation of the SOD1 fusion 
proteins in the aggregates.  A representative example of a transfected cell with no apparent 
aggregate formation is shown (Panels 2 and 4) where the yellow fluorescence pattern is more diffuse 
throughout the cell.  However, small punctate red spots can be observed with DM-Cherry (white 
arrow in Panel 2) and green punctate (white arrow in Panel 4) with DM-EGFP that may represent 
early stages of SOD1 aggregate formation. 
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Immunoprecipitation (IP) pull down assay experiments (Figure 4) were performed to corroborate 
the confocal microscopy data.  IPs were performed on cells co-transfected with (pWT-EGFP /pDM-
Cherry) and the reciprocal (pWT-Cherry /pDM-EGFP) pairings using either anti-GFP or anti-Cherry 
antibodies were probed for the presence of GFP or Cherry fusion proteins.  Figure 4A demonstrates 
that anti-Cherry IP also pulls down GFP-SOD1 protein, and Figure 4B shows that anti GFP IP also pulls 
down Cherry-SOD1 protein.  The recovery of either WT-Cherry-SOD1 or DM-Cherry-SOD1 proteins 
appears to be more efficient using the anti-GFP antibody compared to the recovery of WT-GFP-SOD1 
or DM-GFP-SOD1 with the anti-Cherry antibody.  Normal rabbit serum failed to pull down either GFP 
or Cherry proteins.  These co-precipitation experiments are consistent with a direct interaction 
between WT-GFP-SOD1 and DM-Cherry-SOD1 fusion proteins and between WT-Cherry and DM-
EGFP-SOD1 fusion proteins.  
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Discussion 
The formation of SOD1 aggregates in DM is a pathological feature of the homozygote spinal cord 
(Awano et al., 2009; Nakamae et al., 2015) compared to a much lesser extent in heterozygotes 
although the staining intensity reported in heterozygotes appears to be variable (Awano et al., 2009; 
Nakamae et al., 2015).  Aggregate formation has been described in both neurons and astrocytes 
from homozygotes and a recent study using a DM-SOD1 specific antibody demonstrated that SOD1 
aggregate formation (Awano et al., 2009; Kobatake et al., 2017; Nakamae et al., 2015; Ogawa et al., 
2011) is restricted to heterozygote astrocytes (Kobatake et al., 2017).  In vitro studies of aggregate 
formation and WT:mutant SOD1 interactions described in this study suggest that aggregates in the 
heterozygous scenario may be composed of both WT and mutant SOD1, possibly as protein dimers. 
Although valuable information has been obtained from the use of fluorescent tagged constructs in 
fALS studies (Weichert et al., 2014; Witan et al., 2008; Witan et al., 2009) and DM (Crisp et al., 2013; 
Nakamae et al., 2015), the presence of a relative large protein tag may compromise some of the 
physiological properties of SOD1 (Stevens et al., 2010; Qualls et al., 2013).  However, a recent study 
using a GFP based bicistronic expression system and a standard GFP fusion expression vector 
reported that both DM-SOD1 and the fusion protein GFP:DM-SOD1 form aggregates in SHSY5 
neuroblastoma cells (Draper et al., 2016) suggesting the covalent linkage of a fluorescent tag does 
not significantly alter properties of the native SOD1.  Using the native gel NBT system, we also show 
enzymatic activity of the SOD1 fusion proteins, albeit to a variable degree.  The apparent difference 
in the WT-SOD1 and DM-SOD1 activity regions within the native gel raises the possibility that the 
DM-SOD1 protein form a distinct protein complex profile possibly involving chaperones such as the 
copper chaperone for SOD1 (CCS) that can influence the maturation of an active SOD1 complex 
(Banci et al., 2012).  
Although there is variability in disease penetrance, an important and fundamental difference 
between DM and SOD1 associated fALS is the relatively high frequency of DM homozygotes 
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compared to the relatively high incidence of fALS heterozygotes.  The fALS D90A SOD1 mutation is 
unusual in that both heterozygous and homozygous pedigrees have been reported and with variable 
penetrance for both (Andersen et al., 1995).  Our data strongly suggests some degree of WT:mutant 
SOD1 heterodimeric interaction in neuroblastoma co-transfectants, which subsequently form 
aggregates.  Since aggregates are found in both neurones and astrocytes in DM homozygotes but 
apparently only present in heterozygous astrocytes (Kobatake et al., 2017), this suggests that the 
cellular environment, possibly related to protein clearance pathways may influences the fate of the 
various forms of the SOD1 complexes. 
Studies from fALS in vitro models have shown that wild type SOD1 can influence the folding and 
stability of mutant SOD1, possibly through heterodimer formation (Weichert et al., 2014; Witan et 
al., 2008).  Furthermore, the co-expression of WT and mutant SOD1 constructs in transgenic models 
of fALS also results in a more severe phenotype with an earlier onset (Prudencio et al., 2010; Wang 
et al., 2009; Xu et al., 2015).  The significance of SOD1 aggregates in heterozygote dogs in relation to 
the low incidence of DM in heterozygotes remains unknown.  
In conclusion, the main observation from this study is that DM and wild type SOD1 can interact and 
possibly form heterodimers.  While such an interaction has been described for some fALS associated 
SOD1 mutants, this is the first report for the DM associated mutant and wild type SOD1 protein 
interaction.  DM is a naturally occurring large animal neurological condition and a potential model of 
fALS, although in contrast to fALS penetrance is high in mutant SOD1 homozygotes compared to 
heterozygotes.  It could be speculated that this interaction influences SOD1 complex stability, 
toxicity and ultimately (depending on genetic background) disease penetrance.  Extending our 
understanding of these properties and their impact on disease progression will be important given 
the therapeutic potential of anti SOD1 strategies for treating fALS (Gertsman et al., 2019; Iannitti et 
al., 2018) and DM.  
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Figure 1.  Confirmation of the presence of SOD1 fusion proteins in SK-N-SH transfectants. 
(A) Western blot analysis of lysates from SK-N-SH cells transfected with pEGFP, pWT-EGFP and pDM-
EGFP (left hand panel) and pCherry, pWT-Cherry and pDM-Cherry (right hand panel) for 48 hours 
confirmed the presence of GFP and Cherry SOD1 fusion proteins at ~49 kDa, GFP and Cherry proteins 
at ~27 kDa in cells transfected with the empty vectors and endogenous SOD1 at ~20 kDa.  Images 
captured by fluorescent microscopy (B) show a predominantly cytoplasmic distribution of 
fluorescence in pEGFP and pCherry transfectants.  A representative example WT SOD1 fusion protein 
transfected cells lacking aggregates and DM-SOD1 fusion protein transfected cells with aggregates is 
shown (arrows). 
The density of cells that display aggregates was quantified (C) in a defined area at 20x magnification 
from four independent experiments.  The difference in the density of aggregate containing cells was 
statistically significant (p=0.0086 for pWT-EGFP versus pDM-EGFP (Students t-test, F ratio of 1.02) 
and p= 0.0145 for pWT-Cherry versus pDM-Cherry (Welch t-test, since F ratio =18.5, P=0.03 
confirming unequal variance between data sets). 
Figure 2.  Analysis of SOD1 enzymatic activity by native gel electrophoresis. 
Cell lysates were analysed for SOD1 activity (A) and for the presence of fusion proteins (B). The 
various transfection treatments were:- Non-transfected SK-N-SH cells (Lane 1), cells transfected with 
pWT-EGFP (Lane 2), pDM-EGFP (Lane 3), pWT-EGFP and pDM-Cherry (Lane 4), pWT-Cherry (Lane 5), 
pDM-Cherry (Lane 6) and pWT-Cherry and pDM-EGFP (Lane 7).  Endogenous SOD1 activity (A) is 
indicated by the black arrows and present in all lanes.  Additional bands were identified in cells 
expressing the EGFP recombinants (green arrows) and Cherry recombinants (red arrows).  The 
banding pattern appeared to differ between the WT and DM-SOD1 fusion proteins (compare Lanes 2 
and 3).  The enzymatic activity of the mutant SOD1-Cherry protein (A, Lane 6) was weak compared 
to the other constructs.  (B)  Western blots of the same cell lysates confirmed the presence of SOD1 
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fusion proteins.  The upper panel in B demonstrates the presence of endogenous SOD1 (Lanes 1-7) 
and SOD1 fusion proteins (Lanes 2-7).  The presence of the appropriate fluorescent tag was 
confirmed for GFP (B, middle panel, Lanes 2, 3, 4 and 7) and Cherry (B, lower panel, Lanes 4-7). 
Figure 3.  Confocal microscopy analysis of cells co-expressing wild type and mutant cDNAs.  
Representitive confocal images of SK-N-SH cells co-transfected with pWT-EGFP /pDM-Cherry (Panels 
1 and 2) and pWT-Cherry /pDM-EGFP (Panels 3 and 4) depict the presence and absence of 
aggregates .  The nuclei for each example is stained with DAPI.  The merged images displayed areas 
of punctate yellow fluorescence (Panels 1 and 3) suggesting a co-localisation in the aggregates.  A 
representative example of a transfected cell shows no apparent aggregates (Panels 2 and 4) where 
the yellow fluorescence pattern is more diffuse throughout the cell.  Small punctuate red spots 
(arrow) can be observed with pDM-Cherry (Panel 2) and green puncta (arrow) with pDM-EGFP 
(Panel 4) that may represent early stages of aggregate formation.  (Scale bar=10 µm). 
 
Figure 4. Co-immunoprecipitation of cells co-expressing wild type and mutant cDNAs.  
Evidence for a protein : protein interaction between GFP and Cherry fusion proteins was assessed by 
co-immunoprecipitation.  Lysates from co-transfectants (WT-EGFP/DM-Cherry, DM-EGFP/WT-
Cherry) were immunoprecipitated with either anti-GFP or anti-Cherry then assessed by western blot 
with anti-GFP (A) or anti-Cherry (B).  L indicates lysate (1.5ug, 5% of the amount used in the IP 
reaction), E depicts an empty lane, NRS depicts IP with normal rabbit sera, Cherry IP with anti-Cherry 
antibody and GFP-IP with anti-GFP antibody.  The combination of transfected cells is shown above 
each panel.  The immunoprecipitation of the GFP-SOD1 with anti-Cherry and Cherry SOD1 with anti-
GFP is indicated by the arrows and is clearly visible.  The recovery of either WT-Cherry or DM-Cherry 
SOD1 with an anti-GFP antibody appears to be more efficient compared to the recovery of WT-GFP 
or DM-GFP with the anti-Cherry antibody.  
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